Zsofia K. Stadler, MD, has been appointed as the next Editor-in-Chief of JCO Precision Oncology (JCO PO), an ASCO journal. JCO PO is a peer-reviewed, online-only journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and define genomics- and other biomarker-driven clinical care of patients with cancer.
Zsofia K. Stadler, MD
“ASCO is proud to appoint Dr. Stadler to this pivotal role. Her remarkable track record in precision oncology and her forward-thinking approach to data and technology will be invaluable as we enter a new era of cancer care,” said ASCO Chief Executive Officer Clifford A. Hudis, MD, FACP, FASCO. “We look forward to seeing the journal grow under her leadership."
Dr. Stadler is an Attending Physician and Clinic Director of the Clinical Genetics Service at Memorial Sloan Kettering Cancer Center (MSK), where she also holds a secondary appointment in the Gastrointestinal Medical Oncology Service. A Professor of Medicine at Weill Cornell Medical College, Dr. Stadler’s clinical expertise centers on the management of inherited cancer predispositions, specifically Lynch syndrome.
An accomplished researcher, Dr. Stadler serves as co-primary investigator of MSK’s tumor-normal IMPACT sequencing protocol, a landmark project for which she received the 2025 AACR Team Science Award. Her work, supported by the National Institutes of Health and numerous foundations, focuses on utilizing genomic technologies to identify new cancer susceptibility genes and develop novel screening strategies for high-risk families.
Dr. Stadler completed her medical training at Cornell University and her postgraduate fellowships at Harvard University’s Brigham and Women’s Hospital and Beth Israel Deaconess Medical Center.
In addition to her new role as Editor-in-Chief of JCO PO, she has been an active member of JCO PO since its inception, first as part of the Editorial Board and then as an Associate Editor.
“I am honored to serve as Editor-in-Chief of JCO PO, building on the exceptional foundation established by Dr. James Ford. As genomics and AI become central to routine care, our goal is to translate complex data into actionable insights,” said Dr. Stadler. “I look forward to positioning the journal as a catalyst for innovation, advancing biologically informed therapeutics and ensuring the equitable implementation of precision oncology worldwide.”
Dr. Stadler will begin serving as Editor-in-Chief of JCO PO on July 1, 2026.
